The only treatment for celiac disease is strict adherence to a gluten-free diet and, in an ideal world, compliance with this treatment would reverse all symptoms and physical attributes of the disease (i.e. damage to the small intestine). Unfortunately, that is not always the case; many patients continue to experience a wide range of symptoms and, in some cases, persistent intestinal damage in the form of villous atrophy (flattened villi). Researchers at Columbia University sought to more closely analyze these cases.
5/23/2017
Medication Use Associated with Persistent Villous Atrophy
Recent Posts
- Attention Researchers: CDMRP Funding Opportunities Now Available
- Meet Jennifer, Advocate and CDF Assistant Director of Community Engagement
- Addressing Health Equity and Clinical Disparities – Marilyn’s Message February 2024
- Underrepresented Populations in Celiac Disease, A New Grant, and Collaborations to Improve Health Equity in Celiac Disease
Search the archive
Categories
- Advocacy News
- Celiac Disease in the News
- Clinical Trials
- Eat! Gluten-Free
- Featured
- Foundation Press
- iCureCeliac
- Marilyn’s Message
- Monthly eNewsletter
- Patient Profile Advocacy Series
- Research News
- Research Press
- Trending Topics
Marilyn's Message
2/29/2024
Read moreAddressing Health Equity and Clinical Disparities – Marilyn’s Message February 2024
As we continue our journey toward advancing awareness and understanding of celiac disease, it is crucial that we reflect on health equity and the persistent clinical disparities within our community—so that together we can confront these factors and dismantle barriers hindering access to care and support. Health equity represents the...